Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Emmanuele De Luca"'
Autor:
Elena Ghiso, Cristina Migliore, Vito Ciciriello, Elena Morando, Annalisa Petrelli, Simona Corso, Emmanuele De Luca, Gaia Gatti, Marco Volante, Silvia Giordano
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 12, Pp 1012-1021 (2017)
The Yes-associated protein (YAP) is a transcriptional co-activator upregulating genes that promote cell growth and inhibit apoptosis. The main dysregulation of the Hippo pathway in tumors is due to YAP overexpression, promoting epithelial to mesenchy
Externí odkaz:
https://doaj.org/article/5b0194973dbb42878aa6575f0f3e243f
Publikováno v:
Cancer Management and Research. 12:3721-3729
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and predominantly develops in patients with liver cirrhosis. In patients with advanced disease, such as extra-hepatic extension or portal vein involvement, and with intermediate
Autor:
Pietro Quaglino, Elena Margherita Presotto, Fausto Roila, Andrea Antonuzzo, Diego Cortinovis, Alessandro Peri, Emmanuele De Luca, Gian Domenico Sebastiani, Marco Danova, Fabio Calabrò, Florian Scotté, Luca Giacomelli, Ferruccio Farroni, Maria Francesca Egidi, Francesco Spina, Giuseppe Pasqualetti, Karin Jordan, Massimo Di Maio, Paolo Bossi, Enrico Tagliaferri
Publikováno v:
Oncologist
The safety and activity of immune checkpoint inhibitors have been characterized in interventional and observational studies. However, only small studies have specifically investigated these agents in patients who are excluded or underrepresented in c
Autor:
Marco Tagliamento, Paolo Bironzo, Hubert Curcio, Emmanuele De Luca, Daniele Pignataro, Simonetta G. Rapetti, Marco Audisio, Valentina Bertaglia, Chiara Paratore, Maristella Bungaro, Emanuela Olmetto, Elisa Artusio, Maria Lucia Reale, Clizia Zichi, Enrica Capelletto, Simona Carnio, Lucio Buffoni, Francesco Passiglia, Silvia Novello, Giorgio Vittorio Scagliotti, Massimo Di Maio
Publikováno v:
Critical Reviews in Oncology/Hematology. 172:103639
Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) in pre-treated asMM.A systematic re
Publikováno v:
Transl Lung Cancer Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58792d2fab77ce8da9300c6b515784d6
https://europepmc.org/articles/PMC7225132/
https://europepmc.org/articles/PMC7225132/
Autor:
Emmanuele De Luca, Francesca Mazzoni, Maria Giuseppa Vitale, Massimo Di Maio, Alessio Cortellini, Corrado Ficorella, Ugo De Giorgi, Francesco Atzori, Giuseppe Fornarini, Antonio Maestri, Sara Elena Rebuzzi, Melissa Bersanelli, Diana Giannarelli, Elena Verzoni, Silverio Tomao, Pietro Di Marino, Veronica Mollica, Roberto Sabbatini, Giovanni Schinzari, Sebastiano Buti, Mariella Sorarù, Michele De Tursi, Giuseppe Procopio, Sabrina Rossetti, Claudia Mucciarini, Pierangela Sepe, Teodoro Sava, Leonardo La Torre, Francesco Massari, Marcello Tiseo, Ernesto Rossi, Giuseppe Luigi Banna, Vanja Vaccaro, Stefano Panni, Valentino Martelli
Publikováno v:
Immunotherapy. 12(2)
Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS ana
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:1899-1902
Autor:
Rosario F Di Stefano, Clizia Zichi, Silvia Novello, Giorgio V. Scagliotti, Eleonora Ghisoni, Maria Lucia Reale, Francesco Perrone, Annapaola Mariniello, Leonardo Muratori, Elena Trevisi, Gianmarco Leone, Pasquale Lombardi, Emmanuele De Luca, Massimo Aglietta, Cristina Sonetto, Massimo Di Maio, Anna La Salvia, Paolo Bironzo, Daniele Pignataro, Laura Marandino
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Objectives We previously reported that quality of life (QoL) is not included among trial endpoints and QoL results are underreported in a significant proportion of phase III oncology trials. Here we describe QoL adoption, reporting and methodology of
Autor:
Fotios, Loupakis, Rossana, Intini, Chiara, Cremolini, Armando, Orlandi, Andrea, Sartore-Bianchi, Filippo, Pietrantonio, Nicoletta, Pella, Andrea, Spallanzani, Emanuela, Dell'Aquila, Mario, Scartozzi, Emmanuele, De Luca, Lorenza, Rimassa, Vincenzo, Formica, Francesco, Leone, Lorenzo, Calvetti, Giuseppe, Aprile, Lorenzo, Antonuzzo, Federica, Urbano, Hans, Prenen, Francesca, Negri, Samantha, Di Donato, Pasquale, Buonandi, Gianluca, Tomasello, Antonio, Avallone, Fable, Zustovich, Roberto, Moretto, Carlotta, Antoniotti, Lisa, Salvatore, Maria Alessandra, Calegari, Salvatore, Siena, Federica, Morano, Elena, Ongaro, Stefano, Cascinu, Daniele, Santini, Pina, Ziranu, Marta, Schirripa, Federica, Buggin, Alessandra Anna, Prete, Ilaria, Depetris, Paola, Biason, Sara, Lonardi, Vittorina, Zagonel, Matteo, Fassan, Massimo, Di Maio
Publikováno v:
European journal of cancer (Oxford, England : 1990). 118
Despite the well-known negative prognostic value of theTwo large retrospective series ofA total of 395These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These too
Autor:
Lorenzo Fornaro, Cindy Neuzillet, Rosella Spadi, Francesco Montagnani, Alfredo Falcone, Caterina Vivaldi, Mario Clerico, Francesco Leone, Aurélia Meurisse, Maria Antonietta Satolli, Pasquale Lombardi, Gianna Musettini, Elisa Sperti, Enrico Vasile, Emmanuele De Luca, Dewi Vernerey, Astrid Lièvre, Andrea Casadei-Gardini, Paola Buscaglia, Angélique Vienot, Julien Edeline, Alessandro Passardi, Clémence Brac, Giulia Pasquini, Massimo Aglietta
Publikováno v:
Clinical Colorectal Cancer
Clinical Colorectal Cancer, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩
Clinical Colorectal Cancer, Elsevier, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩
Clinical Colorectal Cancer, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩
Clinical Colorectal Cancer, Elsevier, 2019, 18 (4), pp.e394-e401. ⟨10.1016/j.clcc.2019.08.004⟩
International audience; BACKGROUND:FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f72964521fd495410e0838ed28b94cbd